Last reviewed · How we verify
NCT06417554
A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
Phase 1/Phase 2 trial testing SHR-A2102 in Advanced Solid Tumors in 80 participants. Currently enrolling.
1 July 2027
Quick facts
| Lead sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 13 May 2024 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR-A2102 — full drug profile →
- SHR-A2102 ; Adebrelimab injection — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
RP2D
Time frame: through phase IB completion, an average of 1 years -
Incidence and severity of AE；
Time frame: from Day1 to 90 days after last dose -
ORR
Time frame: 18 months after the last subject was enrolled in the group
Sponsor's own description
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06417554
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SHR-A2102
Trials testing the same drug.
- NCT07414953 — A Phase Ib Study of HS-10504 Combined Therapy in NSCLC · Phase 1 · not yet recruiting
- NCT07041437 — Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer · Phase 2 · not yet recruiting
- NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06589778 — A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Sm · Phase 1, PHASE2 · recruiting
- NCT05701709 — Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
- NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
- NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
- NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
- NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06417554 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
- Last refreshed: 29 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06417554.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing